Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 454 | 59 | 393 |
| Samples | 174 | 29 | 143 |
| Peptides | 168 | 19 | 148 |
Function
CRP · C-reactive protein
The protein encoded by this gene belongs to the pentraxin family which also includes serum amyloid P component protein and pentraxin 3. Pentraxins are involved in complement activation and amplification via communication with complement initiation pattern recognition molecules, but also complement regulation via recruitment of complement regulators. The encoded protein has a calcium dependent ligand binding domain with a distinctive flattened beta-jellyroll structure. It exists in two forms as either a pentamer in circulation or as a nonsoluble monomer in tissues. It is involved in several host defense related functions based on its ability to recognize foreign pathogens and damaged cells of the host and to initiate their elimination by interacting with humoral and cellular effector systems in the blood. Consequently, the level of this protein in plasma increases greatly during acute phase response to tissue injury, infection, or other inflammatory stimuli. Elevated expression of the encoded protein is associated with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. [provided by RefSeq, Aug 2020].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 136 amino-acid changes on canonical ENST00000255030 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CRP · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CRP – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Melanoma | 1/210 0% | 40/1899 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 7/810 1% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 12/1390 1% |
| Other Solid Cancers | 2/94 2% | 14/1515 1% |
| Endometrial Carcinoma | 0/42 0% | 6/612 1% |
| Biliary Tract Carcinoma | 0/54 0% | 5/950 1% |
| Gastric Carcinoma | 1/74 1% | 8/1809 0% |
| Neuroendocrine Tumour | 2/154 1% | 1/577 0% |
| Bladder Carcinoma | 0/58 0% | 4/956 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Thyroid Gland Carcinoma | 3/45 7% | 3/1592 0% |
| Colorectal Carcinoma | 2/143 1% | 8/3239 0% |
| Other Sarcomas | 0/69 0% | 2/699 0% |
| B-Cell Non-Hodgkins Lymphoma | 3/88 3% | 3/2534 0% |
| Breast Carcinoma | 0/144 0% | 7/3264 0% |
| Pancreatic Carcinoma | 2/89 2% | 1/1611 0% |
| Head and Neck Carcinoma | 0/85 0% | 3/1574 0% |
| Ovarian Carcinoma | 0/109 0% | 2/998 0% |
| B-Lymphoblastic Leukemia | 0/55 0% | 4/2640 0% |
| Other Blood Cancers | 2/61 3% | 2/2725 0% |
| Glioma | 0/52 0% | 3/2127 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Kidney Carcinoma | 0/85 0% | 2/1862 0% |
| Neuroblastoma | 0/87 0% | 1/1331 0% |
| Prostate Carcinoma | 0/13 0% | 1/2105 0% |
| Hepatocellular Carcinoma | 0/46 0% | 1/2210 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 1/2550 0% |
Mutation Distribution
Where CRP is mutated · all tissues, split by cell line vs tissue
How many mutations in CRP were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 454 mutations in CRP
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|